Prevalence, prognosis and the possibilities of prevention of ulcus cruris

Tijekom 1999. godine na Odjelu za kožne i spolne bolesti Kliničke bolnice Osijek pregledano je 185 bolesnika s ulkusom potkoljenice: 72,43% bile su žene, a 27,57% muškarci. Na bolničkom liječenju iste je godine bilo 137 bolesnika, što čini 26,39% ukupnog broja bolnički liječenih bolesnika. Prosječna je dužina boravka na odjelu bolesnika s ulkusom bila 17,6 dana, a broj dana provedenih na liječenju je iznosio ukupno 2423. Liječenje ulkusa predstavlja uglavnom veliki problem, financijski zahtjevan.During 1999. 185 patients with ulcus cruris were examined at the Department of Dermatovenerology, Osijek Clinical Hospital. 72.43% were females and 27.57% males. 137 patients were hospitalized which is 26,39% of all hospitalized patients. The average length of hospitalisation for those patients was 17.6 days. The total number of hospital days for patients with ulcus cruris was 2423. The management of ulcus cruris mostly presents a great problem and involves high cost

Prevalence and basic characteristic of psoriasis vulgaris in the city of Osijek

Terenskim istraživanjem obuhvaćeno je na području grada Osijeka 300 stanovnika, sa ciljem da se ustanovi prevalencija psoriasis vulgaris (PV). Vulgarna psorijaza je dijagnosticirana u 44 ispitanika (20 žena i 24 muškarca), što predstavlja prevalenciju od 1,46 % i odnos od 1,2:1 na štetu muškaraca. Kod žena se bolest javlja nešto ranije, i to najviše u periodu do 20 godina života, a kod muškaraca između 20 — 29-te godine. Pozitivni anamnestički podaci o postojanju PV nekog od članova obitelji, dobiveni u 27,3 % psorijatičnih bolesnika, ukazuju da genetsko opterećenje igra značajnu ulogu u kliničkoj ekspresiji bolesti.A field investigation, aiming to establish the prevalence of Psoriasis vulgaris (PV) in the city of Osijek, included 3000 inhabitants. The disease was diagnosed in 44 examinees (20 females and 24 males), i.e. the prevalence is 1.46%, with the relation of 1.2:1 to the benefit of the females. Females develop the disease somewhat earlier, mostly before the age of 20, whereas in males it appears between the ages of 20 and 29. Positive family history of PV, obtained in 27.3 % of the patients, suggests an important role of genetic load in the clinical expression of the disease

GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PSORIASIS

Hrvatsko dermatovenerološko društvo Hrvatskoga liječničkog zbora ustrojilo je radnu skupinu vodećih hrvatskih stručnjaka koji se bave psorijazom. Radna je skupina kritički proučila mjerodavnu znanstvenu literaturu te donijela smjernice za dijagnostiku i liječenje psorijaze.Croatian dermatovenerological society of the Croatian Medical Association formed the working group which consists of leading experts for psoriasis in Croatia. After a critical analysis of relevant scientific papers, the working group has developed guidelines for the diagnosis and treatment of psoriasi

Epidemiology of Dermatomycosis in the Eastern Croatia – Today and Yesterday

The aim of our investigation was to compare the distribution of dermatomycosis species in Eastern Croatia between two different periods: first period from 1997–2001 year, and second period from 1986–88 year. The outpatients from Department of Dermatovenerology University Hospital »Osijek« with confirmed diagnosis infection Tinea, were selected on the basis o age, gender, localization and dermatomycosis species. During the first period (1997–2001) among 75,691 outpatients Tinea infection was confirmed in 558 (0.73%), while in the second period among 47,832 outpatients there were 126 (0.26%) cases with Tinea, what showed significant increase of fungal infections among population this region. According the age and gender in both periods predominant population were under of the age 16 (40.14%: 41.26%), and female population was predominant (58.60% and 57.14%) in comparison to males (41.39% and 42.85%). The most frequent localization of lesions in period I were cutis glabrae (47.31%), palms and soles (31.36%), capitis (17.38%) and unguis (9.31%) and isolated species were as followed: Trichophyton (39.06%), Microsporum (31.72%) and Candida (28.13%) species. In period II the most frequent localization were palms and soles (40.47%), cutis glabrae (36.50%), capitis (12.69%) and unguis (10.31%). The isolated species in this period were: Trichophyton (80.15%), Candida (12.69%) and Microsporum (4.76%) species. From the data collected during two different periods we can observe 1) increase of fungal infection generally in our region; 2) significant changes in causative species (increase of Microsporum and Candida species infection, but Trichophyton spp still remain the first causative agent); and 3) changes in the localization of lesions

Smjernice za dijagnostiku i liječenje vulgarne psorijaze [Guidelines for the diagnosis and treatment of psoriasis]

Croatian dermatovenerological society of the Croatian Medical Association formed the working group which consists of leading experts for psoriasis in Croatia. After a critical analysis of relevant scientific papers, the working group has developed guidelines for the diagnosis and treatment of psoriasis

Antisynthetase syndrome - a case report

U dvadesetosmogodišnje bolesnice s dominirajućim znacima polimiozitisa i zahvaćanjem plućnog intersticija s pozitivnim nalazom anti-Jo1 protutijela postavljena je sumnja na antisintetaza sindrom. Tijekom sljedeća tri mjeseca pojavile su se ragade i ulceracije na vršcima prstiju. U kasnijem tijeku bolesti javila se slika miješane bolesti vezivnog tkiva udružene s intersticijskom plućnom bolesti uz dominirajuću sliku sistemske skleroze. Liječena je glukokortikoidima uz imunosupresivnu terapiju na koju je stanje uglavnom bilo stabilno, bez značajnije progresije plućnih promjena. Rana dijagnoza i liječenje antisintetaza sindroma utječu na povoljniji tijek i ishod bolesti. Preduvjet za navedeno su dobro definirani dijagnostički kriteriji uz procjenu stanja i adekvatan izbor terapije.Twenty-eight year-old woman with predominant signs of polymyositis, pulmonary interstitium involvement and with positive anti-Jo1 antibodies was suspected for antisynthetase syndrome. Over the next three months sores and ulcerations have appeared at the fingertips. In the later course of the disease clinical picture of mixed connective tissue disease associated with interstitial lung disease, with a dominant picture of systemic sclerosis have emerged. She was treated with glucocorticoides and immunosuppressive therapy. Patient condition was mostly stable, without significant progression of lung lesions. Early diagnosis and treatment antisynthetase syndrome significantly contributes to more favorable course and outcome of disease. A prerequisite for that are well-defined diagnostic criteria and an appropriate choice of treatment

GUIDELINES FOR DIAGNOSIS, THERAPY AND FOLLOW UP OF ANDERSON-FABRY DISEASE

Fabryjeva bolest (Anderson-Fabryjeva bolest) jedna je od najčešćih lizosomskih bolesti nakupljanja (nakon Gaucherove bolesti) uzrokovana smanjenom aktivnošću enzima α-galaktosidaze A (α -Gal A) uz posljedično nakupljanje globotriaozilceramida u različitim stanicama, ponajprije u endotelnim i vaskularnim glatkim mišićnim stanicama uz posljedične multisistemske manifestacije. Pojavnost bolesti u muškaraca je 1:40.000-60.000, dok je u općoj populaciji oko 1 : 117.000. Bol je najčešće prvi simptom bolesti u 60-80 % djece, kao i simptomi probavnog sustava, oftalmološki simptomi, gubitak sluha. Smanjenje bubrežne funkcije, hipertrofična miokardiopatija ili moždani udar mogu se iskazati kao izolirani simptomi bolesti. U bolesnika s Fabryjevom bolešću skraćuje se očekivani životni vijek i to u muškaraca za oko 20 godina, a u žena za 10-15 godina, pa je stoga uvođenje nadomjesne enzimske terapije nužno u svih bolesnika koji zadovoljavaju kriterije za terapiju ove bolesti bez obzira na dob i spol.Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the α-galactosidase A (α-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. Estimates of the incidence range from one per 40,000 to 60,000 in males, and 1:117,000 in the general population. Pain is usually the first symptom and is present in 60%-80% of affected children, as well as gastrointestinal disturbances, ophthalmologic abnormalities and hearing loss. Renal failure, hypertrophic cardiomyopathy, or stroke as the presenting symptom may also be found even as isolated symptoms of the disease. Life expectancy is reduced by approximately 20 years in males and 10-15 years in females, therefore enzyme replacement therapy should be introduced in patients of any age and either sex, who meet treatment criteria for Anderson-Fabry disease

Smjernice za dijagnosticiranje, terapiju i praćenje Anderson-Fabryjeve bolesti

Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal storage diseases (after Gaucher disease) caused by deficient activity of the α-galactosidase A (α-Gal A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, predominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. Estimates of the incidence range from one per 40,000 to 60,000 in males, and 1:117,000 in the general population. Pain is usually the first symptom and is present in 60%-80% of affected children, as well as gastrointestinal disturbances, ophthalmologic abnormalities and hearing loss. Renal failure, hypertrophic cardiomyopathy, or stroke as the presenting symptom may also be found even as isolated symptoms of the disease. Life expectancy is reduced by approximately 20 years in males and 10-15 years in females, therefore enzyme replacement therapy should be introduced in patients of any age and either sex, who meet treatment criteria for Anderson-Fabry disease.Fabryjeva bolest (Anderson-Fabryjeva bolest) je jedna od najčešćih lizosomskih bolesti nakupljanja (nakon Gaucherove bolesti) uzrokovana smanjenom aktivnošću enzima α-galaktosidaze A (α -Gal A) uz posljedično nakupljanje globotriaozilceramida u različitim stanicama, ponajprije u endotelnim i vaskularnim glatkim mišićnim stanicama uz posljedične multisistemske manifestacije. Pojavnost bolesti u muškaraca je 1:40.000-60.000, dok je u općoj populaciji oko 1:117.000. Bol je najčešće prvi simptom bolesti u 60%-80% djece, kao i simptomi probavnog sustava, oftalmološki simptomi, gubitak sluha. Smanjenje bubrežne funkcije, hipertrofična miokardiopatija ili moždani udar mogu se iskazati kao izolirani simptomi bolesti. Očekivani životni vijek se skraćuje u bolesnika s Fabryjevom bolešću i to u muškaraca za oko 20 godina, a u žena za 10-15 godina, stoga je uvođenje enzimske nadomjesne terapije nužno u svih bolesnika bez obzira na dob i spol koji zadovoljavaju kriterije za terapiju ove bolesti